Day One Biopharmaceuticals EBIT

The latest EBIT for DAWN is $-120M as of December 2025. That compares with $-220M in the prior-year period — up 44.8% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Day One Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, DAWN's EBIT moved from $-220M to $-120M — a 44.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Day One Biopharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, DAWN currently prints $-120M for EBIT, while the sector average sits near $22B. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Day One Biopharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-120M for DAWN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting DAWN's EBIT ($-120M), review year-over-year change from $-220M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.